<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01645241</url>
  </required_header>
  <id_info>
    <org_study_id>DEX005</org_study_id>
    <nct_id>NCT01645241</nct_id>
  </id_info>
  <brief_title>Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation</brief_title>
  <official_title>Evolutive Potential of Embryos Obtained From Oocytes After Luteal Phase Ovarian Stimulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Universitari Dexeus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FUNDACION DEXEUS SALUT DE LA DONA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ayudas Merck Serono de Investigación 2012</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Universitari Dexeus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the clinical pregnancy rate per embryo transfer in
      oocytes recipients obtained after ovarian stimulation during the luteal phase of oocytes
      donors . This study will be performed in egg recipients and donors but this type of treatment
      is meant to be implemented in fertility preservation patients
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pregnancy rate</measure>
    <time_frame>six weeks after transfer procedure</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Mature oocytes</measure>
    <time_frame>Day of oocyte retrieval</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>INFERTILITY</condition>
  <condition>Fertility Preservation</condition>
  <condition>Ovulation Induction</condition>
  <condition>Vitrification</condition>
  <condition>Oocyte Donation</condition>
  <arm_group>
    <arm_group_label>Lutheal phase ovarian stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early luteal phase Controlled ovarian hyperstimulation: we will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix to induce luteolysis and FSHr (dose according to BMI and AFC )IU/day for controlled ovarian hyperstimulation until achieving criteria for hCG , to induce final oocyte maturation. Mature oocytes will be vitrified. After warming, oocytes will be inseminated by ICSI with the recipients partners semen sample . Recipient endometrium will be primed with estrogen and progesterone , and embryo transfer will be performed on the 3rd day 3 of embryo cleavage.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gonadotropins plus GnRH antagonists</intervention_name>
    <arm_group_label>Lutheal phase ovarian stimulation</arm_group_label>
    <other_name>Ovarian stimulation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ganirelix</intervention_name>
    <arm_group_label>Lutheal phase ovarian stimulation</arm_group_label>
    <other_name>the investigators will administer in the 13th-15th cycle day simultaneously 0.25 mg/day of ganirelix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  premenopausal women, 18-35 years old, FSH levels &lt; 10 mIU/ml; AFC&gt; 10

          -  regular cycles

          -  BMI &lt; 28

          -  signed informed consent

        Recipients:

          -  Infertile women eligible for oocytes donation

          -  BMI &lt; 35

          -  Signed informed consent form

        Exclusion Criteria:

        -Polycystic ovarian syndrome, gonadotropins allergy

        Recipients:

          -  Women eligible for oocytes donation

          -  BMI &gt;35

          -  Uncontrolled Endocrine Pathology
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisca Martínez, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundación Dexeus Salut de la Dona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departamento de Obstetricia Ginecologia y Reproducción. Institut Universitari Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08037</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.dexeus.com</url>
  </link>
  <reference>
    <citation>Sönmezer M, Türkçüoğlu I, Coşkun U, Oktay K. Random-start controlled ovarian hyperstimulation for emergency fertility preservation in letrozole cycles. Fertil Steril. 2011 May;95(6):2125.e9-11. doi: 10.1016/j.fertnstert.2011.01.030. Epub 2011 Feb 3.</citation>
    <PMID>21292255</PMID>
  </reference>
  <reference>
    <citation>von Wolff M, Thaler CJ, Frambach T, Zeeb C, Lawrenz B, Popovici RM, Strowitzki T. Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase. Fertil Steril. 2009 Oct;92(4):1360-5. doi: 10.1016/j.fertnstert.2008.08.011. Epub 2008 Oct 18.</citation>
    <PMID>18930226</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2012</study_first_submitted>
  <study_first_submitted_qc>July 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2012</study_first_posted>
  <last_update_submitted>October 24, 2014</last_update_submitted>
  <last_update_submitted_qc>October 24, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2014</last_update_posted>
  <keyword>Ovarian stimulation</keyword>
  <keyword>Luteal phase</keyword>
  <keyword>Egg donors</keyword>
  <keyword>Fertility preservation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ganirelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

